


Financial Results of Fiscal Year Ended June 2025

August 14, 2025



(Securities code: 7747 Prime of Tokyo Stock Exchange,
Premier of Nagoya Stock Exchange)

*Note: This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect, or any other forms of damages arising from this translation.*

Contents

1. Summary of Consolidated Financial Results of FYE June 2025

2. Earnings Forecast for FYE June 2026

FYE June 2025 Main Points - 1

Revenue 120,025 Mil.Yen <Year-on-year +11.6%>
Progressed favorably primarily on Medical Division (domestic / overseas)
due to expanding demand

- **Medical Division** ~Strong performance in both Cardiovascular and Non-cardiovascular~
 - Cardiovascular field: Increased mainly in PCI GW and Penetration Catheter in all regions
 - Non-Cardiovascular field: Increased in all regions across all areas including Peripheral, Neurovascular, Abdominal and Gastrointestinal
 - OEM business: Decreased mainly in the U.S. and China
- **Device Division** ~ Slight increase in Medical Components and slight decrease in Industrial Components ~
 - Medical Components business: Increased transactions of cardiovascular inspection catheter components for Asia
 - Industrial Components business: Decreased in overseas leisure-related transactions
- **Impact of increased revenue due to exchange rate fluctuation (Yen depreciation) +309 Mil. Yen**

Exchange rate (Unit : JPY)	US \$	EURO	CNY	BAHT
FYE June 2025	149.72	162.83	20.73	4.41
FYE June 2024	149.39	161.48	20.64	4.17

FYE June 2025 Main Points - 2

Operating income 30,079 Mil. Yen <YoY +35.9%>

Net income 12,737 Mil. Yen <YoY -19.4%>

Operating income increased significantly due to a significant improvement in the gross profit margin.
But Net income for the current period decreased due to the recording of impairment losses.

- **Gross profit: 81,235 Mil.Yen < YoY +17.6% >**
 - Increased due to higher sales and an increase in gross profit margin (64.2% → 67.7%) accompanying productivity improvement.
- **Operating income: 30,079 Mil.Yen <YoY +35.9% >**
 - Increased in sales-related expenses both domestically and internationally due to increased revenue and strengthened promotional activities in the U.S. and Japan
 - Increased in R&D expenses (12,248 Mil.Yen) (YoY +585 Mil.Yen, R&D-to-Revenue ratio 10.2 %)
- **Ordinary income: 29,563 Mil.Yen <YoY +34.6% >**
 - Non-operating income: Increased in subsidy income (YoY +838 Mil.Yen)
 - Non-operating expenses: Increased in foreign exchange losses (YoY +1,075 Mil.Yen)
- **Net income attributable to parent company shareholders: 12,737 Mil.Yen <YoY -19.4% >**
 - Extraordinary losses: Booking impairment losses (YoY +9,244 Mil.Yen)
 - Booking loss on valuation of investment securities (YoY +968 Mil.Yen)
 - Booking loss on valuation of shares of subsidiaries and associates, and booking provision of allowance for doubtful accounts for subsidiaries and associates (YoY +687 Mil.Yen)

Highlights Year-on-Year

	FYE June 2024 Results		FYE June 2025 Results				(Reference) At the same exchange rate as the previous year			
	Amount (Mil.Yen)	Ratio (%)	Amount (Mil.Yen)	Ratio (%)	YoY		Amount (Mil.Yen)	Ratio (%)	YoY	
					Changes (Mil.Yen)	Changes (%)			Changes (Mil.Yen)	Changes (%)
Revenue	107,547	100.0	120,025	100.0	+12,477	+11.6	119,715	100.0	+12,168	+11.3
Gross Profit	69,053	64.2	81,235	67.7	+12,182	+17.6	81,849	68.4	+12,796	+18.5
Operating Income excluding goodwill amortization, etc.	24,168	22.5	31,689	26.4	+7,521	+31.1	32,495	27.1	+8,327	+34.5
Operating Income	22,135	20.6	30,079	25.1	+7,943	+35.9	30,891	25.8	+8,755	+39.6
Ordinary Income	21,968	20.4	29,563	24.6	+7,595	+34.6				
Net income attributable to parent company shareholders	15,808	14.7	12,737	10.6	-3,070	-19.4				
EPS (yen)	58.20	—	46.92	—	-11.28	-19.4				

Exchange rate (Unit : JPY)	US \$	EURO	CNY	BAHT
FYE June 2025	149.72	162.83	20.73	4.41
FYE June 2024	149.39	161.48	20.64	4.17

Highlights Compared to the Plan

	FYE June 2025 Revised Plan		FYE June 2025 Results			
	Amount (Mil.Yen)	Ratio (%)	Amount (Mil.Yen)	Ratio (%)	Compared to the Revised Plan	
					Changes (Mil.Yen)	Changes (%)
Revenue	119,160	100.0	120,025	100.0	+864	+0.7
Gross Profit	80,056	67.2	81,235	67.7	+1,178	+1.5
Operating Income excluding goodwill amortization, etc.	30,476	25.6	31,689	26.4	+1,213	+4.0
Operating Income	28,859	24.2	30,079	25.1	+1,220	+4.2
Ordinary Income	28,987	24.3	29,563	24.6	+575	+2.0
Net income attributable to parent company shareholders	11,314	9.5	12,737	10.6	+1,422	+12.6
EPS (yen)	41.66	—	46.92	—	+5.26	+12.6

Exchange rate (Unit : JPY)	US \$	EURO	CNY	BAHT
FYE June 2025 Results	149.72	162.83	20.73	4.41
FYE June 2025 Revised Plan	148.61	161.88	20.49	4.38

Revenue by Segment Year-on-year

	FYE June 2024 Results		FYE June 2025 Results			
	Amount (Mil.Yen)	Ratio (%)	Amount (Mil.Yen)	Ratio (%)	Changes (Mil.Yen)	Changes (%)
Medical	95,654	88.9	107,779	89.8	+12,124	+12.7
Device	11,892	11.1	12,245	10.2	+353	+3.0
Total amount	107,547	100.0	120,025	100.0	+12,477	+11.6

(Reference)

Medical Field	103,180	95.9	115,799	96.5	+12,618	+12.2
Device Field	4,367	4.1	4,226	3.5	-140	-3.2


Operating Income by Segment Year-on-year

	FYE June 2024 Results		FYE June 2025 Results			
	Amount (Mil.Yen)	Operating margin (%)	Amount (Mil.Yen)	Operating margin (%)	Changes (Mil.Yen)	Changes (%)
Operating income excluding goodwill amortization, etc.						
Medical	26,458	27.7	35,055	32.5	+8,596	+32.5
Device	5,287	44.5	4,624	37.8	-662	-12.5
Erasing & Head Quarters	-7,577	—	-7,990	—	-412	+5.4
Total	24,168	22.5	31,689	26.4	+7,521	+31.1
Operating income						
Medical	24,426	25.5	33,445	31.0	+9,019	+36.9
Device	5,287	44.5	4,624	37.8	-662	-12.5
Erasing & Head Quarters	-7,577	—	-7,990	—	-412	+5.4
Total	22,135	20.6	30,079	25.1	+7,943	+35.9
(Reference)						
Device Division Segment Revenue	14,257	—	14,151	—	-106	-0.7


※ Due to organizational expansion at some overseas subsidiaries, etc., the attribution of administrative costs has been changed from Medical/Device segments to Headquarters segment from FYE June 2025. Therefore, the figures adjusted to reflect the allocation of administrative costs for the period FYE June 2024 in line with FYE June 2025. (Correction effect in FYE June 2024 Medical Division -1,762, Device Division -554 ⇒Erasing/Head quarters +2,316)

Earnings Performance by Segment


Revenue



Operating income
excluding goodwill amortization, etc.




Operating income



※ Due to organizational expansion at some overseas subsidiaries, etc., the attribution of administrative costs has been changed from Medical/Device segments to Headquarters segment from FYE June 2025. Therefore, the figures adjusted to reflect the allocation of administrative costs for the period FYE June 2024 in line with FYE June 2025. (Correction effect in FYE June 2024 Medical Division -1,762, Device Division -554 ⇒Erasing/Headquarters +2,316)


Attribution Analysis of Operating Income – 1

(Exchange Rate Fluctuations Included)




Attribution Analysis of Operating Income – 2

(Exchange Rate Fluctuations Excluded)



Situation Per Segment Division

Per Segment by Medical Division (by Geography-1)



【Revenue (YoY)】 ~ Increased due to expanding market share, etc.~

- Japan : Increased primarily in Non-cardiovascular field. Extremely limited impact due to reimbursement price.
 - Cardiovascular field : Increased mainly in Penetration Catheter/Purchased products/Guiding Catheter
 - Non-cardiovascular field : Strong sales of purchased products in Peripheral vascular (Penumbra) and increased in Neurovascular products due to the effect of new product
- Overseas : Increased in all regions due to strong demand and expanding market share across all areas
 - US: Brand products progressed favorably despite the decrease in OEM transactions (Brand products, YoY up +13.6%)
 - Cardiovascular field : Increased mainly in PCI GW/Penetration Catheter
 - Non-cardiovascular field : Increased in all fields including Abdominal vascular, Peripheral vascular and Neurovascular products.
 - OEM Business: Remained flat in existing OEM business due to business partner trends and decreased in REV.1
 - Europe: Progressed well, overall both direct sales and distribution sales
 - Cardiovascular field : Increased PCI GW and Penetration catheter
 - Non-cardiovascular : Increased Neurovascular and Peripheral vascular products.
 - China: Progressed favorably due to the market growth and expanding market share
 - Cardiovascular field : Increased in PCI GW, Penetration Catheter
 - Non-cardiovascular field : Increased in Neurovascular products
 - OEM Business : Decreased transactions due to business partner trends
 - Other: Progressed well, overall
 - Cardiovascular field : Increased in PCI GW mainly in Asia
 - Non-cardiovascular field : Increased in Neurovascular/ Peripheral vascular mainly in Asia
 - OEM Business : Increased transactions due to business partner trends


【Operating Income】 Operating income increased in proportion to revenue

Per Segment by Medical Division (by Geography-2)

(Mil. Yen)		FYE June 2024 Results	FYE June 2025 Results	YoY	
				Changes	Changes (%)
Exchange rate (Yen)	USD	149.39	149.72	+0.33	+0.2
	EURO	161.48	162.83	+1.35	+0.8
	CNY	20.64	20.73	+0.09	+0.4
Total Revenue		95,654	107,779	+12,124	+12.7
Japan		14,727	16,074	+1,346	+9.1
Overseas		80,927	91,705	+10,778	+13.3
US		21,066	23,043	+1,977	+9.4
Europe		22,121	24,148	+2,026	+9.2
China		24,033	28,283	+4,250	+17.7
Other		13,705	16,229	+2,523	+18.4
Operating income		24,426	33,445	+9,018	+36.9

※ Due to organizational expansion at some overseas subsidiaries, etc., the attribution of administrative costs has been changed from Medical/Device segments to Headquarters segment from FYE June 2025. Therefore, the figures adjusted to reflect the allocation of administrative costs for the period FYE June 2024 in line with FYE June 2025. (Correction effect in FYE June 2024 Medical Division -1,762, Device Division -554 ⇒Erasing/Head quarters +2,316)


Per Segment by Medical Division (by Treatment-1)



Per Segment by Medical Division (by Treatment-2)

(Mil. Yen)		FYE June 2024 Results	FYE June 2025 Results	YoY	
				Changes	Changes(%)
Exchange rate (Yen)	USD	149.39	149.72	+0.33	+0.2
	EURO	161.48	162.83	+1.35	+0.8
	CNY	20.64	20.73	+0.09	+0.4
Total Revenue		95,654	107,779	+12,124	+12.7
	Japan	14,727	16,074	+1,346	+9.1
	Overseas	80,927	91,705	+10,778	+13.3
	Cardiovascular	72,690	81,202	+8,512	+11.7
	Japan	8,443	8,629	+186	+2.2
	Overseas	64,246	72,572	+8,326	+13.0
	Non-Cardiovascular	15,346	18,983	+3,636	+23.7
	Japan	4,587	5,799	+1,211	+26.4
	Overseas	10,758	13,184	+2,425	+22.5
	OEM	7,618	7,593	-24	-0.3
	Japan	1,696	1,645	-51	-3.0
	Overseas	5,921	5,948	+26	+0.5

Per Segment by Device Division-1



【Revenue (YoY)】

Slightly increased in medical components and slightly decreased in industrial components

Medical Component

- Japan : Remained flat
- Overseas : Increased transactions of cardiovascular inspection catheter components for Asia

Industrial Component

- Japan : Remained flat
- Overseas : Decreased leisure-related transactions

【Operating income】

Decreased due to a decrease in intersegment transaction, despite the increase in revenue

Per Segment by Device Division-2

(Mil. Yen)		FYE June 2024 Results	FYE June 2025 Results	YoY	
				Changes	Changes (%)
Exchange rate (Yen)	USD	149.39	149.72	+0.33	+0.2
Total Revenue		11,892	12,245	+353	+3.0
	Japan	2,732	2,805	+72	+2.7
	Overseas	9,159	9,439	+280	+3.1
Medical Components		7,525	8,019	+494	+6.6
	Japan	1,082	1,103	+21	+2.0
	Overseas	6,443	6,916	+472	+7.3
Industrial Components		4,367	4,226	-140	-3.2
	Japan	1,650	1,702	+51	+3.1
	Overseas	2,716	2,523	-192	-7.1
Operating income		5,287	4,624	-662	-12.5
(Reference) Segment Revenue		14,257	14,151	-106	-0.7

※ Due to organizational expansion at some overseas subsidiaries, etc., the attribution of administrative costs has been changed from Medical/Device segments to Headquarters segment from FYE June 2025. Therefore, the figures adjusted to reflect the allocation of administrative costs for the period FYE June 2024 in line with FYE June 2025. (Correction effect in FYE June 2024 Medical Division -1,762, Device Division -554 ⇒Erasing/Head quarters +2,316)


Reference: P/L

	FYE June 2024 Results		FYE June 2025 Results			
	Amount (Mil. Yen)	Ratio (%)	Amount (Mil. Yen)	Ratio (%)	Changes (Mil. Yen)	Main comparison factors
Revenue	107,547	100.0	120,025	100.0	+12,477	•Progressed favorably centered in Medical Division
Cost of sales	38,494	35.8	38,789	32.3	+295	
Gross profit	69,053	64.2	81,235	67.7	+12,182	•Increased in proportion to increasing revenue and gross profit margin
SGA	46,917	43.6	51,155	42.6	+4,238	•Increased in expenses related to sales and R&D
Operating income excl. goodwill amortization	24,168	22.5	31,689	26.4	+7,521	
Operating income	22,135	20.6	30,079	25.1	+7,943	
Non-operating income	515	0.5	1,401	1.2	+885	•Increased in subsidy income
Non-operating expense	683	0.6	1,918	1.6	+1,234	•Increased in foreign exchange losses
Ordinary income	21,968	20.4	29,563	24.6	7,595	
Extraordinary income	21	0.0	123	0.1	+102	
Extraordinary loss	199	0.2	11,031	9.2	+10,831	•Recording of impairment losses and increased in loss on valuation of investment securities, etc.
Net income attributable to parent company shareholders	15,808	14.7	12,737	10.6	-3,070	
Comprehensive income	22,873	21.3	9,375	7.8	-13,498	Decreased in line with the foreign exchange rate fluctuation

Reference: B/S

		FYE June 2024 Results		FYE June 2025 Results			
		Amount (Mil. Yen)	Ratio (%)	Amount (Mil. Yen)	Ratio (%)	Changes (Mil. Yen)	Main comparison factors
Assets	Current assets	94,696	49.4	103,359	53.5	+8,662	Cash and deposits +18,542 Inventories -4,692
	Fixed assets	96,917	50.6	89,827	46.5	-7,089	Goodwill -6,800
Total assets		191,614	100.0	193,187	100.0	+1,573	
Liabilities	Current liabilities	29,494	15.4	27,856	14.4	-1,638	Short-term borrowings -3,228 Income taxes payables +2,106
	Fixed liabilities	10,157	5.3	13,976	7.2	+3,818	Long-term borrowings + 5,546 Deferred tax liabilities - 2,714
Total liabilities		39,652	20.7	41,833	21.7	+2,180	
Total net assets		151,961	79.3	151,354	78.3	-607	Retained earnings +7,204 Treasury stock - 4,446 Foreign currency translation adjustment - 2,826
Total liabilities & net assets		191,614	100.0	193,187	100.0	+1,573	

Reference: C/F



Contents

1. Summary of Consolidated Financial Results of FYE
June 2025

2. Earnings Forecast for FYE June 2026

Vision for FYE June 2026

Steady growth in both Medical and Device divisions is expected to boost sales and profits despite negative factors such as the negative impact of assumed exchange rates and increased U.S. tariffs

- **Revenue is expected to reach to 130,870 Mil. Yen (YoY +9.0%) due to growing overseas sales in Medical Division**
 - **Revenue YoY at the same exchange rate as the previous year +11.3%**
(Revenue may decrease due to assumed exchange rate trends (yen appreciation) -2,761 million yen)
 - Medical Division: Cardiovascular/Increase in all overseas market
Non-cardiovascular/ Increase in all overseas market and in all fields due to market penetration
 - Device Division: Increase due to the consolidation of Nitta Mold as a subsidiary, with growth in both Medical components and Industrial components
- **Operating income is expected to reach to 32,642 Mil. Yen (YoY +8.5%) despite the impact of exchange rate fluctuation and tariffs**
 - **Revenue YoY at the same exchange rate as the previous year +16.9%**
 - **Gross profit 86,786 Mil. Yen (YoY +6.8%)**
 - Despite the productivity improvement, etc., GPM may decrease from 67.7% to 66.3% due to exchange rate trends and the impact of US tariffs, etc. (GPM excluding forex rate 67.2%)
 - **SGA expenses 54,144 Mil. Yen (YoY+5.8%)**
 - Increase in expenses for strengthening sales promotion mainly in the U.S.
 - Increase in R&D expenses (12,900 Mil. Yen, revenue ratio 9.9%)
 - Increase in personnel expenses, etc. to strengthen the management foundation
 - Decrease in goodwill amortization (YoY -1,179 Mil. Yen)
 - **Ordinary income 32,809 Mil. Yen(YoY +11.0%)**
 - **Net income attributable to parent company shareholders:23,811 Mil. Yen (YoY +86.9%)**
 - Decrease in impairment losses (YoY -9,244 Mil. Yen),etc.

Exchange rate (Unit : JPY)	US\$	EURO	CNY	BAHT
FYE June 2026 Plan	143.00	165.00	20.00	4.60
FYE June 2025 Results	149.72	162.83	20.73	4.41

Effect of exchange rate on operating income (Main currency)



US \$ (+ 1 yen influence) : approx.	148 Mil. Yen Increase
EURO (+ 1 yen influence) : approx.	123 Mil. Yen Increase
CNY (+ 1 yen influence) : approx.	1,490 Mil. Yen Increase
BAHT(+0.1 yen influence) : approx.	372 Mil. Yen Decrease

Earnings Forecast for FYE June 2026

	FYE June 2025 Results		FYE June 2026 Plan				(Reference) At the same exchange rate as the previous year			
	Amount (Mil.Yen)	Ratio (%)	Amount (Mil.Yen)	Ratio (%)	YoY		Amount (Mil.Yen)	Ratio (%)	YoY	
					Changes (Mil.Yen)	Changes (%)			Changes (Mil.Yen)	Changes (%)
Revenue	120,025	100.0	130,870	100.0	+10,844	+9.0	133,631	100.0	+13,606	+11.3
Gross profit	81,235	67.7	86,786	66.3	+5,550	+6.8	89,785	67.2	+8,549	+10.5
Operating income	30,079	25.1	32,642	24.9	+2,562	+8.5	35,173	26.3	+5,093	+16.9
Ordinary income	29,563	24.6	32,809	25.1	+3,246	+11.0				
Net income attributable to parent company shareholders	12,737	10.6	23,811	18.2	+11,073	+86.9				
EPS (Yen)	46.92	—	88.30	—	+41.38	+88.2				


Exchange rate (Unit : JPY)	US \$	EURO	CNY	BAHT
FYE June 2026 Plan	143.00	165.00	20.00	4.60
FYE June 2025 Results	149.72	162.83	20.73	4.41

Earnings Forecast by Segment




Attribution Analysis of Operating Income – 1

(Exchange Rate Fluctuations Included)




Attribution Analysis of Operating Income - 2

(Exchange Rate Fluctuations Excluded)



R&D Expenses


Continuing aggressive investment in both new and existing projects
<Criteria : R&D to Revenue ratio upper limit 12%>



Results and Plan for Equipment Installation

**Capital investment is generally complete
although an increase is expected due to the launch of factory in China**

Main investment matter (Mil. Yen)	FYE June 2022 Results	FYE June 2023 Results	FYE June 2024 Results	FYE June 2025 Results	FYE June 2026 (Plan)
Expansion of New Building in Seto		3,559	4,224		
Expansion of Shizuoka R&D Center			776	1,099	
Expansion of Thailand factory	869	1,213	717		507
Expansion of Hanoi factory		1,396	1,114	1,448	
Expansion of Cebu factory	1,579	749		691	
Launch of factory in China					1,536



※Excluding amortization transferred to amortization of goodwill, etc.

Caution Regarding Information Presented

All forward looking statements contained herein, including revenue forecasts, outlooks, and strategic plans, are based on the best currently available data; however, risk and uncertainty are involved in these statements.
Please note that actual results may differ greatly from plans presented here.

【 IR contact 】

Asahi Intecc Co., Ltd.
corporate strategic office

TEL 0561-48-5551

URL <https://www.asahi-intecc.co.jp/en>